2.2 Data Licensing

Multi-modal data drives our differentiation

Tempus is helping transform drug discovery by breaking down information silos to link clinical, DNA, RNA, and whole slide pathology imaging data modalities together. With this structured data, we can power AI and machine learning approaches to accelerate drug development for patients.


oncology patients

with treatment and outcomes to power large real-world evidence studies


match patient records

with comprehensive genomic profiling to understand driver mutations and outcomes associations


multi-modal records

with DNA, transcriptomic, clinical, and/or digital pathology images for interrogating tumor biology and mechanisms of action

*Numbers shown indicate data as of March 2021.

Tempus has built the world’s largest library of clinical and molecular data, is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab


Access Tempus data in multiple ways,
to suit your research needs


Lens is a cloud-based Platform as a Service used by pharma, biotech, and academia to derive actionable insights from Tempus’ multi-modal data assets. Lens provides on-demand access to Tempus data through an optimized cloud environment with all the data, analysis tools and compute needed to get to the answers you need. 

Lens empowers users to rapidly extract value and insights in minutes instead of months. Learn more.


Data licensing and subscriptions give you full access and data downloads to power your research initiatives. Data is updated regularly as we continually expand our database.

TEMPUS|Explore: Gain insight in weeks rather than months or years by working with Tempus experts through Explore. Using the entire database, Tempus researchers answer queries to accelerate target identification, biomarker validation, gene expression analysis, clinical trial patient determination, and much more.


Inquire about collaboration opportunities with Tempus AI and Machine Learning Experts to support your drug development programs. We’ve established machine learning partnerships with numerous biopharmaceutical
companies focused on areas such as:

  • Risk and response predictions with multimodal input
  • Histogenomics™ – Image-based molecular biomarker predictions
  • Tumor microenvironment characterization

Get in touch with a member of our team to learn more.


The Lens Platform

With Tempus’ data and the Lens Platform, collaborators are launching pragmatic AI applications, accelerating the pace of development and commercialization.

Explore Tempus data insights to identify disease biomarkers and develop targeted drugs and clinical trials for specific patient types.Lens offers multiple use cases to support drug development:

  • Discover trends in treatments and related outcomes through data selection, profiling, and analytics tools to identify relevant cohorts, explore patterns, and summarize data
  • Validate targets with one of the market’s largest multi-modal datasets
  • Characterize diseases in more granular ways analyzing co-expression or expression signatures
  • Design trials for precisely-defined patient populations
  • Bring your own models or work with our AI team to launch a multi-scale modeling approach


Target Discovery using Molecular Signatures of Pancreatic Ductal Adenocarcinoma (PDAC) with Tempus Data

Learn how our partners are using Tempus data to support target discovery.

Download Case Study

Learn more about building and analyzing datasets to power your research: